Abstract: Objective: To assessment the clinical efficacy and safety of 2% carteolol eye drops combined with mucopolysaccharide polysulfate cream in the treatment of low and medium risk infantile hemangioma. Methods: The infant with low and medium risk superficial infantile hemangioma in our hospital were recruited and randomly divided into experimental group and control group. The patients in experimental group were given topical 2% carteolol eye drops combined with mucopolysaccharide polysulfate cream. The patients in control group were given topical 2% carteolol eye drops. The clinical efficacy and adverse reactions in the two groups were assessed. Results: From December 2016 to November 2020, a total of 218 patients were recruited, including 113 in the experimental group and 105 in the control group. The effective rates in the experimental group at 1, 3, and 6 months of treatment were 18.58%, 55.75%, and 76.11%, which in the control group were 18.10%, 52.38%, 72.38%. There was no statistical difference of the effective rates between the two groups (Ps＞0.05). Adverse reactions included eczema and ulcers, and the incidence of adverse reactions at 6 months of treatment in the experimental group was 1.77%, which was lower than 9.52% in the control group, with a significant difference (P＜0.05). Conclusion: Mucopolysaccharide polysulfate cream does not affect the clinical efficacy of 2% carteolol eye drops in the treatment of low and medium risk superficial hemangioma, while it can reduce the incidence of eczema and ulcers. 

Key words: hemangioma, carteolol, mucopolysaccharide polysulfate cream